Abstract: A catheter for removable insertion into a body vasculature has at least one inflatable member. The catheter has at least in part an expandable body that forms an internal axially extending lumen in at least the expanded state of the body. The inflatable member is adjacent a distal axial end of the body and is configured to at least partially obstruct the lumen.

Abstract: Embodiments concern an optical eye-contact device comprising a lens body having a symmetry axis and which further comprises a light-transmissive portion and an opaque portion, wherein the light-transmissive portion is decentered with respect to the symmetry axis.

Abstract: A method for evaluating a treatment for a brain condition, including: extracting one or more microstate parameter values from at least one EEG signal that was measured after the treatment; and evaluating at least one parameter of the treatment based on the one or more microstate parameter values.

Abstract: Embodiments relate to an implantable device for detecting leakage of matter from a mammalian lumen, the device comprising a mesh structure that is attachable to a lumen of a mammalian. The mesh structure comprises a material or a material composition that is electrically conductive and which is measurably responsive in terms of its electrical conductivity when being subjected to leakage of matter from the lumen.

Abstract: The invention provides isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within said peptides. Pharmaceutical compositions comprising said peptides and antibodies are also disclosed as well as methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.

Abstract: According to some embodiments there is provided an anastomosis device configured to reduce leakage, comprising: a first set of rings sized to be positioned at a first tissue wall; a second set of rings sized to be positioned at a second tissue wall adjacent the first tissue wall; and an element configured to draw the ring sets towards each other; wherein each set of rings comprises an inner ring, an outer ring, and a coupling for aligning the inner and outer rings with respect to each other; wherein the inner ring applies a first pressure onto the tissue wall which is sufficient to gradually form a passage between the first and second tissue walls; and the outer ring applies a second pressure onto the tissue wall, the second pressure applied radially outwardly relative to the first pressure, the second pressure sufficient to reduce leakage in a vicinity of the passage.

Abstract: Use of activated protein C (APC) for treatment and prevention of ocular diseases, disorders or conditions associated with retinal leakage and CNV such as age-related macular degeneration, optionally in combined therapy with anti-angiogenesis, anti-inflammatory, immunosuppressive, and anti PDGF agent.

Abstract: Described herein are methods for determining the prognosis of a patient diagnosed with Acute Lymphoblastic Leukemia (ALL), and particularly determining the risk of disease relapse following standard treatment. Also described are systems of treatment that are directed by a health care provider, and which include the described prognostic methods and the treatments recommended for patients determined to have a specific relapse risk.

Abstract: Described herein is the correlation between miR-451 expression and the increased benefit of a treatment modality of solid tumors that effects miR-451 modulated metabolic pathways. Such modalities include NAMPT inhibitors and/or PARP inhibitors. Also described herein are methods for treatment of solid tumors that include determining whether treatment of the tumor would benefit from inhibition of NAMPT and/or PARP and if so, treating the patient afflicted with the tumor with NAMPT and/or PARP inhibitors.

Abstract: A method for repairing a perforation in a tympanic membrane comprising attaching a single patch to an undersurface of the tympanic membrane covering the perforation.

Abstract: An ophthalmic surgical instrument for fragmenting the lens nucleus of an eye, and method of use thereof. The instrument includes an elongated handle portion, a tubular head portion at the handle portion distal end, at least three prongs with cutting tips, and a holding ring. The prongs are selectively retractable into and deployable from the head portion. The holding ring selectively contracts and expands to adjust the deployment width of the prongs. The instrument is inserted toward the eye lens through a corneal incision, while the head portion is opened to deploy the prongs to slide over and grasp onto the lens nucleus at a posterior position thereof. The instrument is then withdrawn toward the eye lens anterior while the head portion is closed to retract the prongs, such that the prong cutting tips cut along the lens nucleus, so as to fragment the lens nucleus into multiple segments.

Abstract: Using microstate data to evaluate Alzheimer's disease including dementia and/or mild cognitive impairment and/or depression and optionally provide treatment based on the diagnosis and/or modify treatment and/or diagnosis based on response to treatment, optionally as measured using microstate data. In one example, the method includes analyzing EEG data to generate one or more EEG parameter; and generating a risk for one or both of depression and MCI (mild cognitive impairment) based on said one or more EEG parameters. Optionally, the disease comprises MCI. Optionally, the disease comprises depression. Optionally, the one or more EEG parameter comprises a microstate-derived parameter. Optionally, the one or more EEG parameter comprises a microstate duration derived parameter.

Abstract: A method of treating an inflammatory disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), wherein the fraction comprises cannabis derived active ingredients other than the THCA.

Abstract: This disclosure relates to compositions for use in treatment of Alzheimer's Disease, and/or a ocular and retinal degenerative disease, such as age related macular degeneration. The described compositions include effective amounts of LLMe, the hydrobromide form thereof, or functional derivatives thereof. Methods of treatment of a retinal degenerative disease of Alzheimer's Disease using the described compositions are also provided.

Abstract: A method for evaluating a treatment for a brain condition, including: extracting one or more microstate parameter values from at least one EEG signal that was measured after the treatment; evaluating at least one parameter of the treatment based on the one or more microstate parameter values.

Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.

Abstract: A method for preventing bleeding, blood-brain barrier disruption, brain injury, or a combination thereof in a subject destined for cardiac surgery is disclosed. The method involves administering to the subject prior to cardiac surgery a therapeutically effective amount of alpha-1 antitrypsin (AAT-1), or functional variant thereof. The result is that it prevents bleeding, blood-brain barrier disruption, or a combination thereof in a subject destined for cardiac surgery.

Abstract: The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of ALL patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of miR-151-5p and miR-451 in a test sample. The invention thereby also provides methods and kits for monitoring and early diagnosis of cancerous disorders associated with low miR-151-5p and/or miR-451 expression, specifically ALL, and appropriate associated treatments thereof.

Abstract: A method of treating a malignant disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a first liquid chromatography fraction of a Cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), and a therapeutically effective amount of a second liquid chromatography fraction of a Cannabis extract comprising at least 75% cannabigerolic acid (CBGA), wherein the first liquid chromatography fraction comprises Cannabis derived active ingredients other than the THCA, and the second liquid chromatography fraction comprises Cannabis derived active ingredients other than the CBGA, thereby treating the malignant disease in the subject.

Abstract: A system for vital sign measuring of a patient, comprising: a first sensor removably attachable with a first body portion of the patient and configured to measure, when in operable position, a vital sign of the patient; at least one additional sensor removably attachable with a second body portion of the patient and configured to measure, when in operable position, a vital sign of the patient; and a processor configured to provide data descriptive of a level of correspondence between measurements of the vital signs provided by the first sensor and the at least one additional sensor.